您当前的位置：
首页 >
文章列表页 >
A comprehensive clinical evaluation of first-line toripalimab in six cancers
Drug and Clinical Practice | 更新时间：2026-10-28

    • A comprehensive clinical evaluation of first-line toripalimab in six cancers

    • Chin J Hosp Pharm   Vol. 46, Issue 17, Pages: 2026-2037(2026)

    • DOI：10.13286/j.1001-5213.2026.17.09    

      CLC： R979.1

    • Published：15 September 2026

    移动端阅览

  • LI Wen,CHEN Ying,YAO Kaijie,et al.A comprehensive clinical evaluation of first-line toripalimab in six cancers[J].Chin J Hosp Pharm,2026,46(17):2026-2037. DOI： 10.13286/j.1001-5213.2026.17.09.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Severe immune-related liver injury induced by toripalimab combined with chemotherapy: a case report
Comprehensive clinical evaluation of moxifloxacin injections from different manufacturers in treating community-acquired pneumonia in the context of the Centralized Procurement Policy
Analysis of adverse reaction characteristics of PD-1 inhibitors in Shandong Province based upon real-world monitoring data
Pharmacoeconomic evaluation of three domestic PD-1 inhibitors for advanced non-small cell lung cancer
Exploration on criteria and compromise of prescription review of Chinese patent medicines Ⅴ:drug selection in older patients

Related Author

LI Cuilin
TAN Yani
LIU Xin
YANG Yuping
ZHANG Haixia
CHEN Dayu
GU Qiaoling
XU Yuan

Related Institution

Department of Pharmacy, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University
Department of Respiratory and Critical Care Medicine， Nanjing Drum Tower Hospital
a.Department of Pharmacy
Department of Pharmacy， Nanjing Drum Tower Hospital， School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University
Department of Drug Monitoring， Shandong Medicine Adverse Reaction Monitoring Center
0